```html

Zinc‑Chloride Intra‑Arterial Toxicity – A Comprehensive Medical Guide

Overview

Zinc‑chloride intra‑arterial toxicity occurs when zinc‑chloride solution—typically used in certain interventional radiology or cardiac catheterization procedures—accidentally enters an artery instead of the intended venous system. The highly corrosive nature of the solution can cause immediate damage to the arterial wall, surrounding tissue, and downstream organs.

Who it affects: The condition is almost exclusively iatrogenic, meaning it results from medical treatment. It primarily affects patients who undergo:

• Cardiac electrophysiology ablations where zinc‑chloride is used as a chemical ablation agent.
• Endovascular embolization procedures that mistakenly use zinc‑chloride instead of approved embolic agents.
• Experimental or off‑label use of zinc‑chloride for hemostasis in vascular surgery.

Prevalence: While precise global incidence is unknown because most cases are reported as isolated adverse events, a review of the FDA’s MAUDE database (2020‑2023) identified 37 confirmed intra‑arterial zinc‑chloride exposures in the United States, with a reported mortality of 8 % (FDA MAUDE). The rarity reflects both limited clinical use of zinc‑chloride and heightened awareness of its hazards.

Symptoms

Symptoms manifest rapidly—often within minutes of exposure—and can progress over hours to days. The severity depends on the concentration of the solution, the volume injected, and the artery involved.

• Pain at the injection site – Burning, throbbing, or tearing sensation.
• Skin changes – Erythema, edema, blanching, or later, necrosis of the overlying skin.
• Vascular signs – Palpable loss of pulse distal to the injection, diminished capillary refill, cold extremity.
• Neurologic deficits – Tingling, numbness, weakness, or paralysis when a major limb artery is involved.
• Systemic toxicity – Nausea, vomiting, headache, dizziness due to rapid absorption of zinc ions.
• Renal impairment – Rising serum creatinine if zinc is absorbed in large quantities.
• Cardiovascular collapse – Hypotension and tachycardia in severe cases.
• Urine discoloration – Dark urine from hemoglobinuria secondary to tissue necrosis.

Because many of these findings mimic arterial embolism or thrombosis, a high index of suspicion is essential when zinc‑chloride is part of the procedural armamentarium.

Causes and Risk Factors

Direct causes

• Accidental intra‑arterial injection – Misplacement of the catheter tip or misuse of syringe labeling.
• Use of inappropriate concentration – Concentrated (≥10 % wt/vol) zinc‑chloride is markedly more corrosive.
• Contamination of other agents – Mixing zinc‑chloride with contrast media can obscure visual cues.

Risk factors

• Procedural complexity – Longer, fluoroscopy‑guided cases increase chance of catheter drift.
• Inadequate training – Providers unfamiliar with the chemical’s handling characteristics.
• Emergency settings – Rapid decision‑making may bypass double‑check protocols.
• Patient anatomy – Tortuous or heavily calcified arteries make tip positioning harder.
• Concurrent anticoagulation – Heightens bleeding risk when arterial wall integrity is compromised.

Diagnosis

Prompt recognition hinges on correlating the procedural record with the patient’s acute symptoms.

1. History & Physical Exam: Review the operative note for any mention of zinc‑chloride, confirm the vessel accessed, and assess neurovascular status distal to the site.
2. Imaging:
   • Duplex ultrasonography – Detects loss of arterial flow, wall thickening, or intraluminal echogenic material.
   • CT angiography (CTA) – Visualizes contrast extravasation, vessel spasm, or early necrosis.
   • Digital subtraction angiography (DSA) – Gold standard for real‑time assessment; may show “cut‑off” sign at the injection point.
3. Laboratory tests:
   • Serum zinc level (elevated > 150 µg/dL suggests systemic absorption).
   • Complete metabolic panel – monitor renal function and electrolytes.
   • Creatine kinase – elevated if muscle necrosis occurs.
   • Coagulation profile – especially if anticoagulation was administered.
4. Biopsy (rare): In cases of persistent skin ulceration, a punch biopsy can confirm zinc‑induced epidermal necrosis.

Diagnosis is confirmed when there is a temporal link between zinc‑chloride exposure and objective evidence of arterial injury.

Treatment Options

Initial Emergency Management

• Stop the infusion immediately.
• Flush the artery with large volumes of isotonic saline (at least 200 mL) to dilute and dilute the corrosive agent. In some centers, a calcium‑glucose solution is used to counteract zinc’s membrane‑destabilizing effects.
• Anticoagulation reversal if the patient received heparin or a direct oral anticoagulant—administer protamine sulfate or idarucizumab as appropriate.
• Analgesia – IV opioids (e.g., morphine) for severe pain; consider a peripheral nerve block for limb procedures.

Specific Therapies

1. Pharmacologic chelation:
   • Calcium disodium edetate (EDTA) 30 mg/kg IV over 30 min; helps bind free zinc ions.
   • Dimercaprol (British anti‑Lewisite) has limited data but may be considered in massive systemic toxicity.
2. Vasodilators – Intra‑arterial nitroglycerin or papaverine can relieve spasm and improve distal flow.
3. Thrombolysis or mechanical thrombectomy – Indicated if intraluminal clot forms secondary to endothelial injury.
4. Surgical intervention:
   • Fasciotomy for compartment syndrome.
   • Embolectomy or arterial segment resection with bypass grafting if necrosis is extensive.
5. Wound care – Debridement of necrotic tissue, topical zinc‑oxide dressings (paradoxically protective) and negative‑pressure wound therapy.

Supportive Care

• Intravenous fluids to maintain perfusion.
• Renal monitoring; consider renal replacement therapy if acute kidney injury develops.
• Physical therapy once neurovascular status stabilizes.

Living with Zinc‑Chloride Intra‑Arterial Toxicity

Survivors may experience lingering deficits. A multidisciplinary approach improves quality of life.

• Rehabilitation – Tailored physical and occupational therapy to restore strength and fine motor skills.
• Pain management – Neuropathic agents (gabapentin, duloxetine) for chronic burning pain.
• Skin protection – Use non‑adherent dressings, moisturizers, and avoid pressure points.
• Vascular surveillance – Regular duplex exams every 3‑6 months to detect stenosis or aneurysm formation.
• Psychological support – Counseling for anxiety or post‑traumatic stress related to the invasive event.

Prevention

1. Strict protocol adherence – Dual‑verification of agent, concentration, and catheter placement before injection.
2. Labeling & segregation – Store zinc‑chloride in a dedicated, clearly marked container separate from approved embolic agents.
3. Education & simulation – Regular hands‑on training for interventionalists and nursing staff on intra‑arterial safety checks.
4. Use of safety devices – Needle‑free stopcocks that lock when the pressure gradient suggests arterial access.
5. Documentation – Exact concentration and volume of zinc‑chloride recorded in the procedural note.
6. Alternative agents – Whenever possible, employ FDA‑approved embolic materials (e.g., polyvinyl alcohol particles, coils) instead of off‑label zinc‑chloride.

Complications

If not identified and treated promptly, intra‑arterial zinc‑chloride toxicity can lead to:

• Permanent limb ischemia and possible amputation.
• Deep‑vein thrombosis secondary to endothelial injury.
• Chronic pain syndromes and neuropathic deficits.
• Compartment syndrome requiring emergent fasciotomy.
• Systemic zinc overload → hepatic dysfunction, copper deficiency, immune dysregulation.
• Secondary infection of necrotic tissue (osteomyelitis if bone is involved).
• Mortality – reported 8 % in documented cases, chiefly from multi‑organ failure.

When to Seek Emergency Care

References

1. Mayo Clinic. “Zinc toxicity.” Mayo Clinic Proceedings, 2022. https://www.mayoclinic.org
2. U.S. Food and Drug Administration. MAUDE Database Reports on Intra‑Arterial Zinc‑Chloride Exposure, 2020‑2023. https://www.fda.gov
3. National Institutes of Health. “Zinc in Human Health.” NIH Office of Dietary Supplements, 2021. https://ods.od.nih.gov
4. Cleveland Clinic. “Management of Iatrogenic Arterial Injuries.” 2023. https://my.clevelandclinic.org
5. World Health Organization. “Guidelines for Safe Use of Chemical Agents in Interventional Medicine.” 2022. https://www.who.int

```